Phase I study of monoclonal antibody ch14.18/CHO continuous infusion in patients with neuroblastoma
Latest Information Update: 30 May 2019
Price :
$35 *
At a glance
- Drugs Dinutuximab (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- 29 May 2019 Planned number of patients changed from 6 to 9.
- 29 May 2019 Status changed from active, no longer recruiting to completed.
- 06 Jun 2016 New trial record